Related Experiment Video
Updated: Oct 23, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Radiological monitoring of immunotherapy in renal cell carcinoma]
Simon Lennartz1, Thorsten Persigehl1
1Institut für Diagnostische und Interventionelle Radiologie, Uniklinik Köln, Köln, Deutschland.
Abstract:
The Response Evaluation Criteria in Solid Tumours (RECIST 1.1) currently represent the most widely established evaluation criteria for standardised therapy monitoring in solid tumours treated with traditional cytostatic and cytotoxic tumour therapies. The increasing use of immune checkpoint inhibitors in the therapy of metastatic renal cell carcinoma poses special challenges for radiological therapy monitoring due to the presence of atypical response patterns and immunotherapy-specific side-effects. Adapted criteria such as immune RECIST (iRECIST) can help in the follow-up assessment of renal cell carcinoma to detect atypical courses of disease under immune checkpoint inhibitor therapy both within and outside of clinical trials.
Related Concept Videos
Kidney Transplant III: Nursing Management
Imaging Studies VII: Vascular Imaging
Imaging Studies III: Computed Tomography
Acute Kidney Injury IV: Diagnostic Studies and Prevention

